Tufted Angioma

Back

Background

Tufted angiomas are rare vascular tumors characterized by tightly packed capillaries (“tufts”) in discrete lobules scattered through the dermis and, sometimes, subcutaneous tissue. Although adult-onset cases have been described, tufted angiomas occur far more frequently in infants and children. Tufted angiomas usually have a benign course, with only rare reports of aggressive behavior or local invasion.[1] However, tufted angiomas seldom self-involute.[2]

Pathophysiology

The pathogenesis of tufted angiomas is not well understood. Vascular markers (CD31 and CD34), vascular endothelial growth factor receptor-3 (VEGFR-3), and lymphatic markers (D2-40 and PROX1) on the neoplastic cells suggest they may be derived from the endothelial cells of lymphatic vessels.[3, 4]

Epidemiology

Frequency:

Tufted angiomas are rare, and the true incidence is unknown. As of 2015, only 158 cases are described in the English-language literature.[5]

Race:

No racial predilection is recognized for tufted angioma.

Sex:

The prevalence of tufted angioma is equal in males and females.

Age:

Approximately 50% of cases of tufted angiomas present at birth, while most other cases develop within the first year of life.[6] Although rare, there are reports of onset later in childhood and even in adulthood.

Less than 10% of tufted angiomas develop in individuals older than 50 years, and tumors in persons older than 60-80 years are rare.[2, 7] One 81-year-old patient with a tufted angioma of 2 years' duration is reported in the French-language literature, and a case has been described in an 84-year-old man in Japan.[8, 9]

One case report describes a 69-year-old man who was found to have an intracranial tufted angioma, suggesting potential for aggressive behavior and invasion into the brain.[1] Another case describes a 40-year-old man with a 2-year history of a lesion on his lower eyelid, which was confirmed on histology to be a tufted angioma.[10]

Prognosis

Tufted angiomas may spontaneously regress or may regress after treatment, but they do not completely resolve.[6, 11, 12] In fact, in a study of patients 10 years after diagnosis and treatment of tufted angioma, presence of tumor was still evident on repeat biopsy.[13] Pain and tenderness are common associated symptoms, and hyperhidrosis is a frequent finding that occurs in 30% of patients.[14]

The growth pattern of tufted angioma tends to be slow and progressive (ie, occurring over 5 months to 10 years). However, an occasional tufted angioma undergoes a rapid expansion phase that leads to localized swelling and a decreased range of motion of the structures in the affected area. One report described a patient with a painful tufted angioma on the lateral neck and jaw. The tumor also had deep extension into the underlying fascia and muscle, a rare finding.[15]

Residual lesions after treatment of tufted angioma usually looks like one of three patterns: (1) discoloration resembling a port-wine stain with superimposed papules, (2) an indurated area with telangiectasias, or (3) a fibrotic infiltrate within the subcutaneous tissue. Long-term symptoms can include chronic pain and swelling.

Kasabach-Merritt syndrome occurs in association with tufted angioma in approximately 10% of patients. Fortunately, most of these patients have a favorable response to treatment without further sequelae. However, there is a mortality rate of up to 24% in patients with Kasabach-Merritt syndrome.[16] Death in these cases results from bleeding, sepsis, invasion of a vital structure, or organ failure.[17]

Patient Education

Tufted angioma is a benign tumor, with very rare reports of deaths directly or indirectly attributable to complications. However, pain and tenderness are common associated symptoms, and hyperhidrosis is a frequent finding that occurs in 30% of patients.[14]

The growth pattern of tufted angioma tends to be slow and progressive (ie, occurring over 5 months to 10 years). However, an occasional tufted angioma undergoes a rapid expansion phase that leads to localized swelling and a decreased range of motion of the structures in the affected area.

Kasabach-Merritt syndrome, characterized by severely low platelets and coagulopathy, has been reported to occur in 10% of patients with a diagnosis of tufted angioma. Fortunately, most of these patients have a favorable response to treatment.

History

Most tufted angiomas develop by the time the patient is aged 1 year, although a number of juvenile and adult cases have been reported. Tufted angiomas typically manifest as firm, dark-red, reddish-brown, or violet plaques and/or nodules with poorly defined borders. Their size is variable, ranging from less than 1 cm to over 10 cm in diameter.[18]

At birth, the lesions are usually barely evident as slight-pink or brown discoloration with an ill-defined border. Over 1-10 years, the area thickens into a red or violet plaque or patch that can form nodules and papules. Eventually, the tumors tend to stabilize and remain that size indefinitely. Some cases have reported partial or total regression of the tumor during childhood.[19, 20]

Most reported tumors occur on the trunk, arms, and legs, while tumors of the face and scalp are rare.[18] Involvement of the feet and oral mucosa is observed, but only in rare cases.[21, 22] Hypertrichosis with lanugo hairs and hyperhidrosis is often observed overlying the tumor.[18]

Generally, the lesion is described as solitary. However, multifocal or disseminated presentations are reported. In immunosuppressed patients, a rare eruptive form of tufted angiomas has been described.[23] Approximately 10% of patients with tufted angiomas develop the life-threatening Kasabach-Merritt syndrome.

Many tufted angiomas are associated with painful episodes as they increase in size.

Physical Examination

A tufted angioma appears as a purplish-red to red-brown patch or plaque that predominantly appears on the upper thorax; neck; shoulders; and, less commonly, on the face, scalp, and proximal extremities.[24, 25]

The diameter of the patch or plaque generally ranges from less than 1 cm to over 10 cm. The tufted angioma may be solitary (most common) or multifocal (rare), and it can be round to polycyclic in more extensive cases (see the image below). The border is always ill defined.



View Image

This lesion is a tufted angioma in a 1-year-old girl. Present since birth, this bluish-red hemangioma-like plaque on the patient's right upper leg slo....

On palpation, tufted angiomas often have a rubbery consistency, and they may be painful.

Ulceration is rare; this finding may be predicted from its slow rate of growth.

Hyperhidrosis of the skin overlying the area of the tufted angioma is reported. Histologically, hyperhidrosis corresponds with areas of abundant eccrine glands.[7]

Peripheral extension occurs, and lesions of tufted angioma are described as having a thick, indurated border and a central depression, with an appearance similar to that of a doughnut.[14] Tufted angioma lesions may also appear as deep-red or purple patches with scattered round-to-oval, dark-red nodules on their surface.

Causes

No causes of tufted angioma have been established. Trauma does not appear to be a predisposing factor.

Several authors have noted the development of tufted angioma within port-wine stains or in the context of these stains.[26, 27, 28]

Some authors have postulated that high hormonal levels during pregnancy and puberty may induce the development of tufted angiomas.[29, 30] However, these etiologies are not supported in current medical literature as causes of tufted angiomas.

Complications

In approximately 10% of cases, tufted angiomas are associated with a serious life-threatening platelet-trapping syndrome, called Kasabach-Merritt syndrome (KMS). Suspect Kasabach-Merritt syndrome in patients with tufted angioma in whom ecchymotic patches, thrombocytopenia, and/or blood-clotting abnormalities develop. In this setting, rapid enlargement of the lesion accompanied by pain and ecchymosis is the presenting sign of KMS.[31] Along with these signs, the patient has severe thrombocytopenia (3,000-60,000/µL, low fibrinogen levels (16</ref> Responses to a variety of appropriate treatment modalities are noted in patients with Kasabach-Merritt syndrome and tufted angioma.[31, 32]

Approach Considerations

A diagnosis of tufted angiomas is classically suspected in an infant or young child presenting with a red or violet vascular lesion with ill-defined borders present on the trunk or extremities. Hypertrichosis and/or excessive sweating overlaying the lesion further supports a diagnosis of tufted angioma.

Upon suspicion of tufted angioma, a biopsy specimen to obtain histological confirmation should be obtained whenever possible. However, there are times when a biopsy carries more risk than benefit and is deferred, such as when the lesion is highly vascular and/or the patient also presents with thrombocytopenia and coagulopathy. When a risky biopsy is pursued, there should be careful planning and communication between the surgeon, anesthesiologist, hematologist, and pathologist to ensure preparation with platelets, fresh frozen plasma, and other supportive measures if needed intraoperatively and postoperatively.

Laboratory Studies

No specific laboratory study is useful in the diagnosis or treatment of tufted angioma. However, upon diagnosis, laboratory workup of tufted angioma should include a complete blood cell (CBC) count, fibrinogen, D-dimer, prothrombin time (PT), and activated partial thromboplastin time (aPTT). Further evaluation with kidney and liver function tests should also be ordered in severely ill patients. Urinary levels of basic fibroblast growth factor are of no value in the diagnosis of this condition, unlike juvenile capillary angioma.

If the patient has coexistent Kasabach-Merritt syndrome, laboratory tests reveal severe thrombocytopenia, low fibrinogen, and elevated d-Dimer.

Imaging Studies

MRI studies have been proven useful in the examination of patients with deep and/or extensive tufted angiomas. MRI has been successful in evaluating the depth of invasion and extent of growth of tufted angiomas that extend deep into the muscle and fascia, as well as in documenting the response to treatment.[14]

Procedures

Other than biopsy for diagnosis and the surgical and laser treatments described, no other procedures are indicated for tufted angioma.

Histologic Findings

Tufted angiomas have a specific histologic pattern. They are characterized by the lobular arrangement of densely cellular capillaries (tufts), often referred to as a “cannonball” pattern, that are scattered throughout the dermis.[36] The vascular tufts consist of tightly packed hypertrophic endothelial cells with scanty cytoplasm and nuclei that are round, ovoid, or fusiform. Mitoses are rarely seen.

Immunohistochemistry usually reveals positive D2-40 and POX1 staining, while GLUT1 (a marker for infantile hemangiomas) is always negative.

Occasionally, hemosiderin deposits may be observed within the endothelial cells. Capillary spaces are narrow and elongated, and they are more noticeable in the periphery of the lobules, where they have a characteristic half-moon cleft shape.[37]

The capillary lobules are present throughout the dermis and subcutaneous tissue; the epidermis is uninvolved in most cases. Rare cases with fascial and muscular involvement are reported.[14] The surrounding pilosebaceous units of the dermis are unaffected, although hypertrophy of neighboring eccrine sweat glands is reported. No edema or inflammation surrounds the vascular lobules.

Approach Considerations

The treatment for tufted angioma is multimodal and individualized, depending on the extent of tumor invasion, tumor size, presence of symptoms, and presence or absence of Kasabach-Merritt syndrome. Treatment generally consists of one or multiple approaches, including surgical excision, pulsed-dye laser (for superficial tumors), and several medications and chemotherapy agents. The efficacy of one treatment approach over another has not been established in large randomized clinical trials, and current available evidence is based on anecdotal clinical experience, case reports, and small case series.

For patients with small tufted angiomas who are asymptomatic, observation only can be considered. There have been a few reports of patients whose tufted angiomas spontaneously regressed in infancy and childhood.[6, 38, 39]

Medical Care

For patients without Kasabach-Merritt syndrome who are symptomatic and who opt not to have surgical excision or who are not surgical candidates, pharmacological management with aspirin 5 mg/kg/day is first-line treatment.[40]

In patients with unresectable tumors owing to size, location, or surgical risks, pharmacotherapy can be used to decrease the tumor size. Although no single agent or combination of agents has been proven better than another, several chemotherapy agents haven been used, including vincristine, sirolimus (an mTOR inhibitor), interferon-alfa, and systemic corticosteroids. Systemic corticosteroids are often used as first-line therapy to stabilize the platelet count and then slowly tapered.[41] Vincristine administered via a central line is usually given in conjunction with corticosteroids.[42] Sirolimus is an oral chemotherapy agent that is still under investigation for the treatment of infantile vascular tumors.[43] It has been effectively used to treat several cases of tufted angioma, demonstrating it to be a possible promising treatment with good preliminary results. According to a 2016 meta-analysis of 15 clinical studies of various therapies used to treat tufted angioma, results suggest vincristine may be most effective relative to other agents.[44]

 

Hemostasis Support

For patients with coexistent Kasabach-Merritt syndrome, the coagulopathy must be carefully managed with hemostasis support. In these patients, hemorrhage is rare but can occur in disseminated intravascular coagulation (DIC) and multiorgan failure. Despite severely low platelet counts in these patients, platelets should only be given prior to surgery and in patients with active bleeding; platelets administration can rapidly increase the size of and pain associated with the tumor, leading to increased platelet trapping. In patients with low fibrinogen levels, cryoprecipitate should be given if one of the following four conditions is present: (1) active bleeding, (2) in preparation for surgery, (3) platelet count less than 10,000/µL, or (3) a fibrinogen level less than 1 g/L. Recombinant human factor VIIa can be given in cases of active bleeding.[45] Fresh frozen plasma may be required in infants with DIC. Packed red blood cells should be given for symptomatic anemia.

Surgical Care

Complete surgical excision, if chosen, allows permanent removal of small or localized tufted angiomas, although local recurrence of some surgically excised tumors is observed.[46] Surgical excision can be tried as second-line therapy after failure of medical management.[47]

Cryosurgery, radiation therapy, and embolization are successful to varying degrees in tufted angioma patients.[48] Use of the pulsed-dye laser has had variable results in both children and adults with tufted angioma.[11]

Consultations

If Kasabach-Merritt syndrome is suspected in a child, consultation with a hematologist/oncologist and a dermatologist may be indicated.

Prevention

Because the cause of tufted angioma is poorly understood, no specific method of prevention or deterrence is recommended.

Long-Term Monitoring

In patients who opt not to undergo medical or surgical management, tumors should be carefully monitored for size expansion and the development of Kasabach-Merritt syndrome.

Guidelines Summary

For patients without Kasabach-Merritt syndrome with small tumors, surgical excision is first-line management. For nonresectable tumors, patients should be given 5 mg/kg/day of aspirin as the treatment of choice. In patients who are asymptomatic, careful observation for regression is an option.

For patients with Kasabach-Merritt syndrome, surgical excision is the treatment of choice if the tumor is small and localized. However, large or nonresectable tumors should be treated with intravenous vincristine plus systemic corticosteroids or oral sirolimus. Hemostasis support with platelet infusion, fresh frozen plasma, recombinant human factor VIIa, and cryoprecipitate should only be administered to patients who are actively bleeding or being prepared for surgery.

Medication Summary

The use of no one specific drug is indicated in the treatment of patients with tufted angioma. However, anecdotal cases that benefited from several agents are reported; see the list below:

Author

Alexandra R Vaughn, Drexel University College of Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Amanda T Moon, MD, Clinical Assistant Professor of Dermatology, Children's Hospital of Philadelphia

Disclosure: Nothing to disclose.

Specialty Editors

Michael J Wells, MD, FAAD, Dermatologic/Mohs Surgeon, The Surgery Center at Plano Dermatology

Disclosure: Nothing to disclose.

John G Albertini, MD, Private Practice, The Skin Surgery Center; Clinical Associate Professor (Volunteer), Department of Plastic and Reconstructive Surgery, Wake Forest University School of Medicine; Past President, American College of Mohs Surgery

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: QualDerm Partners; Novascan<br/>Have a 5% or greater equity interest in: QualDerm Partners - North Carolina.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Carrie L Kovarik, MD, Assistant Professor of Dermatology, Dermatopathology, and Infectious Diseases, University of Pennsylvania School of Medicine

Disclosure: Nothing to disclose.

Leyda E Bowes, MD, Cosmetic Surgery Fellow, Department of Dermatology, Cosmetic Laser Associates of San Diego County

Disclosure: Nothing to disclose.

Mitchel P Goldman, MD, Voluntary Clinical Professor of Dermatology, University of California, San Diego, Medical Center; Dermatologist, West Dermatology and Cosmetic Laser Dermatology

Disclosure: Nothing to disclose.

References

  1. D'Amico RS, Zanazzi G, Hargus G, Dyster T, Chan S, Lignelli-Dipple A, et al. Intracranial intraaxial cerebral tufted angioma: case report. J Neurosurg. 2017 Feb 24. 1-6. [View Abstract]
  2. Jones EW, Orkin M. Tufted angioma (angioblastoma). A benign progressive angioma, not to be confused with Kaposi's sarcoma or low-grade angiosarcoma. J Am Acad Dermatol. 1989 Feb. 20(2 Pt 1):214-25. [View Abstract]
  3. Arai E, Kuramochi A, Tsuchida T, Tsuneyoshi M, Kage M, Fukunaga M, et al. Usefulness of D2-40 immunohistochemistry for differentiation between kaposiform hemangioendothelioma and tufted angioma. J Cutan Pathol. 2006 Jul. 33 (7):492-7. [View Abstract]
  4. Folpe AL, Veikkola T, Valtola R, Weiss SW. Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol. 2000 Feb. 13 (2):180-5. [View Abstract]
  5. Pesapane F, Nazzaro G, Alberti-Violetti S, Gianotti R. A case of acquired tufted angioma in adulthood. An Bras Dermatol. 2015 May-Jun. 90 (3 Suppl 1):16-8. [View Abstract]
  6. Lee B, Chiu M, Soriano T, Craft N. Adult-onset tufted angioma: a case report and review of the literature. Cutis. 2006 Nov. 78 (5):341-5. [View Abstract]
  7. Ban M, Kamiya H, Kitajima Y. Tufted angioma of adult onset, revealing abundant eccrine glands and central regression. Dermatology. 2000. 201(1):68-70. [View Abstract]
  8. Dewerdt S, Callens A, Machet L, Grangeponte MC, Vaillant L, Lorette G. [Acquired tufted angioma in an adult: failure of pulsed dye laser therapy]. Ann Dermatol Venereol. 1998 Jan. 125(1):47-9. [View Abstract]
  9. Murakami M, Nitta Y, Ikeya T, Hara K. Two cases of angioblastoma (Nakagawa): A one-month baby and an 84-year-old man (in Japanese). Rinsho Derma (Tokyo). 1997. 39:925-9.
  10. Verma J, Singh A, Misra V, Singh SP. Tufted Angioma of Eyelid in an Adult - A Case Report. J Clin Diagn Res. 2016 Jun. 10 (6):ED12-3. [View Abstract]
  11. Robati RM, Hejazi S, Shakoei S, Bidari F. Late-onset tufted angioma with remarkable response to pulse dye laser. Indian J Dermatol. 2014 Nov. 59 (6):635. [View Abstract]
  12. Tlougan BE, Lee MT, Drolet BA, Frieden IJ, Adams DM, Garzon MC. Medical management of tumors associated with Kasabach-Merritt phenomenon: an expert survey. J Pediatr Hematol Oncol. 2013 Nov. 35 (8):618-22. [View Abstract]
  13. Enjolras O, Mulliken JB, Wassef M, Frieden IJ, Rieu PN, Burrows PE, et al. Residual lesions after Kasabach-Merritt phenomenon in 41 patients. J Am Acad Dermatol. 2000 Feb. 42 (2 Pt 1):225-35. [View Abstract]
  14. Suarez SM, Pensler JM, Paller AS. Response of deep tufted angioma to interferon alfa. J Am Acad Dermatol. 1995 Jul. 33(1):124-6. [View Abstract]
  15. Silva RS, Bressan AL, Nascimento LB, Kac BK, Azulay-Abulafia L. Tufted angioma and myofascial pain syndrome. An Bras Dermatol. 2011 Feb. 86(1):125-7. [View Abstract]
  16. Mulliken JB, Anupindi S, Ezekowitz RA, Mihm MC Jr. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 13-2004. A newborn girl with a large cutaneous lesion, thrombocytopenia, and anemia. N Engl J Med. 2004 Apr 22. 350 (17):1764-75. [View Abstract]
  17. Carrington PR. Truncal location of hemangioendotheliomas may indicate potentially more serious involvement with resulting Kasabach-Merritt syndrome than size determinant alone. J Am Acad Dermatol. 2006 May. 54 (5):922-3. [View Abstract]
  18. Herron MD, Coffin CM, Vanderhooft SL. Tufted angiomas: variability of the clinical morphology. Pediatr Dermatol. 2002 Sep-Oct. 19 (5):394-401. [View Abstract]
  19. Lam WY, Mac-Moune Lai F, Look CN, Choi PC, Allen PW. Tufted angioma with complete regression. J Cutan Pathol. 1994 Oct. 21 (5):461-6. [View Abstract]
  20. Miyamoto T, Mihara M, Mishima E, Hagari Y, Shimao S. Acquired tufted angioma showing spontaneous regression. Br J Dermatol. 1992 Dec. 127 (6):645-8. [View Abstract]
  21. Fukunaga M. Intravenous tufted angioma. APMIS. 2000 Apr. 108(4):287-92. [View Abstract]
  22. Kleinegger CL, Hammond HL, Vincent SD, Finkelstein MW. Acquired tufted angioma: a unique vascular lesion not previously reported in the oral mucosa. Br J Dermatol. 2000 Apr. 142(4):794-9. [View Abstract]
  23. Al-Za'abi AM, Ghazarian D, Greenberg GR, Shaw JC. Eruptive tufted angiomas in a patient with Crohn's disease. J Clin Pathol. 2005 Feb. 58 (2):214-6. [View Abstract]
  24. Fujita H, Asahina A, Tamaki K. Extensive tufted angioma of the left arm in a 47-year-old woman. Clin Exp Dermatol. 2009 Oct. 34(7):e216-7. [View Abstract]
  25. McAleer MA, Kirby B, Sheahan K, Collins P. An erythematous patch and plaque on the shoulder--quiz case. Acquired tufted angioma (TA). Arch Dermatol. 2008 Sep. 144(9):1217-22. [View Abstract]
  26. Swerlick RA, Cooper PH. Pyogenic granuloma (lobular capillary hemangioma) within port-wine stains. J Am Acad Dermatol. 1983 May. 8(5):627-30. [View Abstract]
  27. Alessi E, Bertani E, Sala F. Acquired tufted angioma. Am J Dermatopathol. 1986 Oct. 8(5):426-9. [View Abstract]
  28. Kim TH, Choi EH, Ahn SK, Lee SH. Vascular tumors arising in port-wine stains: two cases of pyogenic granuloma and a case of acquired tufted angioma. J Dermatol. 1999 Dec. 26(12):813-6. [View Abstract]
  29. Padilla RS, Orkin M, Rosai J. Acquired "tufted" angioma (progressive capillary hemangioma). A distinctive clinicopathologic entity related to lobular capillary hemangioma. Am J Dermatopathol. 1987 Aug. 9(4):292-300. [View Abstract]
  30. Kim YK, Kim HJ, Lee KG. Acquired tufted angioma associated with pregnancy. Clin Exp Dermatol. 1992 Nov. 17(6):458-9. [View Abstract]
  31. Enjolras O, Wassef M, Dosquet C, et al. [Kasabach-Merritt syndrome on a congenital tufted angioma]. Ann Dermatol Venereol. 1998 Apr. 125(4):257-60. [View Abstract]
  32. Leaute-Labreze C, Bioulac-Sage P, Labbe L, Meraud JP, Taieb A. Tufted angioma associated with platelet trapping syndrome: response to aspirin. Arch Dermatol. 1997 Sep. 133(9):1077-9. [View Abstract]
  33. Frieden IJ, Rogers M, Garzon MC. Conditions masquerading as infantile haemangioma: Part 1. Australas J Dermatol. 2009 May. 50 (2):77-97; quiz 98. [View Abstract]
  34. Fernandez-Pineda I, Parida L, Jenkins JJ, Davidoff AM, Rao BN, Rodriguez-Galindo C. Childhood hemangiopericytoma: review of St Jude Children's Research Hospital. J Pediatr Hematol Oncol. 2011 Jul. 33 (5):356-9. [View Abstract]
  35. Frieden IJ, Rogers M, Garzon MC. Conditions masquerading as infantile haemangioma: Part 2. Australas J Dermatol. 2009 Aug. 50 (3):153-68; quiz 169-70. [View Abstract]
  36. Jones EW. Dowling oration 1976. Malignant vascular tumours. Clin Exp Dermatol. 1976 Dec. 1(4):287-312. [View Abstract]
  37. Prieto VG, Shea CR. Selected cutaneous vascular neoplasms. A review. Dermatol Clin. 1999 Jul. 17(3):507-20, viii. [View Abstract]
  38. Osio A, Fraitag S, Hadj-Rabia S, Bodemer C, de Prost Y, Hamel-Teillac D. Clinical spectrum of tufted angiomas in childhood: a report of 13 cases and a review of the literature. Arch Dermatol. 2010 Jul. 146 (7):758-63. [View Abstract]
  39. Browning J, Frieden I, Baselga E, Wagner A, Metry D. Congenital, self-regressing tufted angioma. Arch Dermatol. 2006 Jun. 142 (6):749-51. [View Abstract]
  40. Javvaji S, Frieden IJ. Response of tufted angiomas to low-dose aspirin. Pediatr Dermatol. 2013 Jan-Feb. 30 (1):124-7. [View Abstract]
  41. Ozsoylu S. About the treatment of Kasabach-Merritt syndrome. Pediatr Hematol Oncol. 2000 Dec. 17 (8):727-8. [View Abstract]
  42. Haisley-Royster C, Enjolras O, Frieden IJ, Garzon M, Lee M, Oranje A, et al. Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol. 2002 Aug-Sep. 24 (6):459-62. [View Abstract]
  43. Adams DM, Trenor CC 3rd, Hammill AM, et al. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics. 2016 Feb. 137 (2):e20153257. [View Abstract]
  44. Liu XH, Li JY, Qu XH, Yan WL, Zhang L, Yang C, et al. Treatment of kaposiform hemangioendothelioma and tufted angioma. Int J Cancer. 2016 Oct 1. 139 (7):1658-66. [View Abstract]
  45. Janic D, Brasanac D, Krstovski N, Dokmanovic L, Lazic J, Krstic Z. The use of recombinant activated factor VII during major surgery in a child with Kasabach-Merritt syndrome. Paediatr Anaesth. 2009 Feb. 19 (2):177-9. [View Abstract]
  46. Abass K, Saad H, Kherala M, Abd-Elsayed AA. Successful treatment of kasabach-merritt syndrome with vincristine and surgery: a case report and review of literature. Cases J. 2008 May 23. 1 (1):9. [View Abstract]
  47. Drolet BA, Trenor CC 3rd, et al. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr. 2013 Jul. 163 (1):285-91. [View Abstract]
  48. Descours H, Grézard P, Chouvet B, Labeille B. [Acquired tufted angioma in an adult]. Ann Dermatol Venereol. 1998 Jan. 125(1):44-6. [View Abstract]
  49. Bernstein EF, Kantor G, Howe N, Savit RM, Koblenzer PJ, Uitto J. Tufted angioma of the thigh. J Am Acad Dermatol. 1994 Aug. 31(2 Pt 2):307-11. [View Abstract]

This lesion is a tufted angioma in a 1-year-old girl. Present since birth, this bluish-red hemangioma-like plaque on the patient's right upper leg slowly enlarged and became tender during the month prior to presentation. The child was otherwise well. A skin biopsy specimen revealed dilated congested capillaries in the lower dermis and subcutis. Clusters of capillaries with hyperplastic endothelial cells were also scattered in the mid and upper parts of the dermis. The epidermis revealed a slight basket-weave orthokeratosis, with minimal acanthosis, and papillomatosis. The patient was treated conservatively with only observation. The lesion remained stable and did not progress since presentation. Courtesy of National Skin Centre, Singapore.

This lesion is a tufted angioma in a 1-year-old girl. Present since birth, this bluish-red hemangioma-like plaque on the patient's right upper leg slowly enlarged and became tender during the month prior to presentation. The child was otherwise well. A skin biopsy specimen revealed dilated congested capillaries in the lower dermis and subcutis. Clusters of capillaries with hyperplastic endothelial cells were also scattered in the mid and upper parts of the dermis. The epidermis revealed a slight basket-weave orthokeratosis, with minimal acanthosis, and papillomatosis. The patient was treated conservatively with only observation. The lesion remained stable and did not progress since presentation. Courtesy of National Skin Centre, Singapore.